As TSA or 5-aza-dC treatments increase IL-13Rα2 expression in prostate cancer cells, we determined whether treatment with these epigenetic modulators also altered the sensitivity of prostate cancer cells to Pep-1-Phor21. This evidence concerns the gene IL13RA2 and prostate carcinoma.